Oncology

Latest News

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com

5 Things You Should Know About Skin Cancer

By Pearl Steinzor

May 2nd 2025

As skin cancer rates continue to rise, here are 5 key facts every health care professional should know to improve prevention, early detection, and patient outcomes.

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com

Patient Navigation Is Nonnegotiable in Cancer Care

By Maggie L. Shaw

May 1st 2025

Liver cancer - Sebastian Kaulitzki - stock.adobe.com.jpg

Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

By AJMC Contributor

May 1st 2025

Doctor carrying documentation for patient care | image credit: Kanisorn - stock.adobe.com.jpeg

NCODA Outlines New Patient-Centered Oncology Distribution Models

By Pearl Steinzor

May 1st 2025

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

New Developments Warrant Rethinking HCC Transplant Criteria

By Jared Kaltwasser

April 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

August 4th 2017

5 Developments With Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD

There’s a lot happening in clinical practice with immunotherapy treatments: expanded indications for nivolumab and ipilimumab, biomarkers to judge patient response to combinations, and developments with CAR-T.

August 3rd 2017

Posttreatment Care in Breast Cancer: Oncologist vs PCP Roles

Surabhi Dangi-Garimella, PhD

Provider roles in team-based care in oncology need clarity, and now, results from a new study affirm the confusion experience by patients treated for breast cancer on who should lead their care posttreatment.

August 2nd 2017

Accelerated Approval for Nivolumab for DNA Repair—Deficient Advanced CRC

Surabhi Dangi-Garimella, PhD

The approval follows a review of phase 2 results from CheckMate-142.

August 2nd 2017

CAR-T Cells Can Increase Clinical Remission Rates in Multiple Myeloma Patients

Alison Rodriguez

The new immunotherapy of chimeric antigen receptor (CAR)-T cells has demonstrated the ability to increase clinical remission in multiple myeloma patients by targeting the B-cell maturation protein that participates in disease progression.

August 1st 2017

Enasidenib Approved for IDH2-Mutated Patients With Relapsed/Refractory AML

Surabhi Dangi-Garimella, PhD

Enasidenib (Idhifa), developed by Celgene and Agios, has been granted FDA approval in tandem with a companion diagnostic test to detect IDH-2 mutations.

August 1st 2017

Study Finds Rising Insurer Approvals for Cancer Clinical Trials Since ACA

Christina Mattina

After the Affordable Care Act (ACA) required private insurers to pay the standard-of-care costs for patients participating in approved clinical trials, the rate of patients cleared by their insurer to take part in early-phase oncology trials has increased, a new study has found.

July 31st 2017

The FDA's Roadmap for More Stringent Tobacco Regulation

Surabhi Dangi-Garimella, PhD

The FDA has announced a regulatory plan that could shift the trajectory on tobacco-related disease and death.

July 30th 2017

FDA Expands Approval of Yervoy for Metastatic Melanoma in Pediatric Patients

Alison Rodriguez

The FDA has expanded the indication of Bristol-Myers Squibb’s Yervoy (ipilimumab) to include the treatment of pediatric patients 12 years of age and older with unresectable or metastatic melanoma.

July 28th 2017

Breakthrough Therapy Designation for Venetoclax in AML

Venetoclax (Venclexta), in combination with low dose cytarabine, has been granted a breakthrough therapy designation for use in elderly, treatment-naive patients with acute myeloid leukemia (AML) who cannot handle intensive chemotherapy.

July 27th 2017

MYSTIC Trial Yields Disappointing Results for AstraZeneca's Durvalumab Combination in NSCLC

Christina Mattina

AstraZeneca announced that its immuno-oncology drug durvalumab, in combination with tremelimumab, failed to meet a progression-free survival endpoint in the MYSTIC trial in patients with metastatic non-small cell lung cancer (NSCLC).

July 27th 2017

The Crux: Correlating Surrogate Endpoints With Real-World Evidence in Oncology

Surabhi Dangi-Garimella, PhD

A new study has analyzed data from randomized controlled trials in oncology that used surrogate endpoints and measured their relation with treatment effectiveness and patient survival in the real world.

July 27th 2017

Genetic Tests Can Predict Tumor Aggressiveness and Help Treatment Decisions

Alison Rodriguez

Study used gene biomarker to identify which patients with colon cancer would not benefit from chemotherapy.

July 26th 2017

NCI Panel Discusses Importance of Research on Cancer Survivorship

Christina Mattina

During a panel hosted by the National Cancer Institute (NCI), patient advocates and survivorship experts discussed the strides made in the field of cancer survivorship research.

July 25th 2017

Mechanism for Checkpoint Inhibitor Resistance Identified in Invasive Bladder Cancer

Christina Mattina

Researchers have identified a cellular signaling pathway that when activated by mutations may prevent immune cells from infiltrating bladder tumors, thus making the cancer resistant to immune checkpoint inhibitors.

July 25th 2017

Cost-Effectiveness of a Patient Navigation Program to Improve Cervical Cancer Screening

Yan Li, PhD Erin Carlson, DrPH Roberto Villarreal, MD Leah Meraz, MA José A. Pagán, PhD

This study investigates the cost-effectiveness of a community-based patient navigation program to improve cervical cancer screening.

July 25th 2017

Low-Fat Dietary Patterns Potentially Linked to Lower Breast Cancer Mortality Rate

Alison Rodriguez

The Women’s Health Initiative Dietary Modification Trial examined the long-term influence of low-fat eating patterns on the breast cancer mortality rate.

July 25th 2017

Barriers to Recruiting ED Patients With Advanced Cancer for Palliative Care

Surabhi Dangi-Garimella, PhD

Patient refusal, symptom burden, and diagnostic disparities were identified as some of the most common barriers encountered when recruiting patients with advanced cancer for palliative treatment in the emergency department (ED).

July 25th 2017

Immune-Cell Numbers Determine Combination Immunotherapy Response in Melanoma Patients

Alison Rodriguez

The Journal of Clinical Investigation Insight recently published a study that analyzed 112 different melanoma tumors in attempt to correlate partially exhausted cytotoxic lymphocytes (peCTLs) and regulatory T lymphocyte (Treg) levels with response to combination immunotherapy.

July 24th 2017

Study of 1.7 Million Patients Finds Strong Link Between Teenage Obesity, Colon Cancer Risk

Being overweight or obese as a teenager raises the risk of developing colon cancer later in life, a new study in the journal CANCER has found.

July 24th 2017

Kite's CAR-T Therapy Produces Durable Remission in DLBCL, Study Finds

Christina Mattina

A study on long-term remission of diffuse large B-cell lymphoma (DLBCL) shows that Kite Pharma’s anti-CD19 chimeric antigen receptor-T (CAR-T) cell treatment resulted in remission for up to 56 months.

July 22nd 2017

SEER-Medicare Database Analysis Notes Higher Resource Utilization Among Patients With Neuroendocrine Tumors

Surabhi Dangi-Garimella, PhD

In a study presented at the 2017 American Society of Clinical Oncology Annual Meeting, researchers at MD Anderson Cancer Center used data on 12,052 elderly patients diagnosed with neuroendocrine tumors to analyze their resource utilization.

July 22nd 2017

Brazilian Study Queries: Is NGS Cost-Effective in Advanced Lung Cancer?

Surabhi Dangi-Garimella, PhD

In a study presented at the 2017 American Society of Clinical Oncology Annual Metting, researchers from the Brazilian Cancer Foundation and the Brazilian National Cancer Institute evaluated the cost-effectiveness of a unique exam using next-generation sequencing versus other routine tests.

July 22nd 2017

Adjuvant Chemotherapy Reduces Cost, Improves Survival in NSCLC Post-Surgery

Surabhi Dangi-Garimella, PhD

Including adjuvant chemotherapy in the postsurgical treatment plan in patients with non—small cell lung cancer (NSCLC) improves survival and is cost-effective compared with surgical resection alone, according to analysis results presented at the 2017 American Society of Clinical Oncology Annual Meeting.

July 21st 2017

CT-P6, a Trastuzumab Biosimilar, Shares the Safety and Efficacy Profile of Its Reference

CT-P6, a proposed trastuzumab biosimilar, is safe and effective as a neoadjuvant treatment in HER2—positive early breast cancer, according to research presented at the 2017 American Society of Clinical Oncology Annual Meeting.

July 21st 2017

Research Demonstrates Efficacy and Safety of Trastuzumab Biosimilar SB3

Research presented at the 2017 American Society of Clinical Oncology Annual Meeting showed that SB3, a proposed biosimilar to trastuzumab, has comparable efficacy, safety, immunogenicity, and pharmacokinetics to the reference product based on the breast pathological complete response.

July 21st 2017

Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer

Surabhi Dangi-Garimella, PhD

After switching studies, research in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar, according to results presented at the 2017 Annual Meeting of the American Society of Clinical Oncology.

July 21st 2017

ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation

Surabhi Dangi-Garimella, PhD

The diagnosis of stage I disease increased for female breast cancer, colorectal cancer, and lung cancer following implementation of the Affordable Care Act (ACA), according to research presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago.

This Week in Managed Care: July 21, 2017

July 21st 2017

This Week in Managed Care: July 21, 2017

This week, the top managed care stories included more twists in Senate Republicans' efforts to repeal the Affordable Care Act; a Medicare fraud sweep targeted opioid distribution; and the CDC reported 30 million Americans now have diabetes.

July 21st 2017

Social Interaction Among Patients During Chemotherapy Affects Treatment Response

Alison Rodriguez

Social interaction during chemotherapy treatments can positively influence a cancer patient’s health through improving patient outcomes and patient survival rates.

July 21st 2017

Examining How Online Patient-Reported Outcomes Make a Difference in Cancer Care

Christina Mattina

In a webinar hosted by Carevive, researcher Ethan Basch, MD, MSc, discussed the findings of his recent study linking electronic patient-reported outcomes (PROs) to better survival outcomes for patients with cancer.

...

67 68 69 70 71 72 73 74 75

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions